Truist Securities has initiated coverage on Protagonist Therapeutics (PTGX) with a Buy rating and a $60 price target, citing its promising lead assets and significant market potential. The firm forecasts robust sales for rusfertide and JNJ-2113, highlighting their potential to disrupt the blood cancer and inflammatory diseases markets respectively.